Routine Blood Test Predicts CAR-T Therapy Success in Non-Hodgkin Lymphoma Patients

Physicians at Fox Chase Cancer Center查看公司主页 and Temple Health (搜索)搜索该词条 have identified a simple blood test that could revolutionize how clinicians predict treatment success in non-Hodgkin lymphoma patients receiving CAR-T cell therapy. The research, presented at the 67th American Society of Hematology Annual Meeting and Exposition, demonstrates that measuring absolute lymphocyte count (ALC) provides crucial insights into patient outcomes.

The study found that patients with higher ALC levels and faster rates of ALC increase after therapy experienced significantly better outcomes, including improved progression-free survival, overall survival, and complete response rates. A high concentration of lymphocytes in the blood indicates a strong immune response, making this marker particularly relevant for immunotherapy treatments.

Clinical Significance and Treatment Implications

"If we see that a patient has low ALC and might relapse, we can try another strategy. Finding a kinetic marker that doesn't take a lot of resources to check but could still make a real difference in a patient's course of treatment is exciting," said first author Helen Gandler, MD, a third-year resident in internal medicine at Temple Hospital.

The research addresses a critical need in CAR-T cell therapy management. While this relatively new treatment is initially highly effective in patients whose non-Hodgkin lymphoma has relapsed or resisted other treatments, most patients eventually experience relapse again. Early identification of patients at risk could enable providers to transition to alternative therapies more quickly.

Study Design and Patient Population

Researchers examined the relationship between absolute lymphocyte count and treatment outcomes in patients with relapsed or resistant non-Hodgkin lymphoma who received axicabtagene ciloleucel查看药品详情, marketed as Yescarta查看药品详情. During CAR-T cell therapy, patients' T cells are collected and genetically modified to express a chimeric antigen receptor that helps target and kill lymphoma cells before being infused back into the patient.

Key Research Findings

The study revealed three critical predictive patterns:

Higher baseline ALC correlates with better survival: Patients whose ALC was above-median at treatment initiation demonstrated significantly longer progression-free survival and higher overall survival rates.

Faster ALC increase indicates stronger response: Patients whose ALC increased most rapidly in the first 10 days post-treatment showed greater complete response rates and longer progression-free survival.

Early peak suggests favorable prognosis: Patients whose ALC peaked sooner experienced better survival outcomes overall.

Practical Implementation Advantages

The findings represent the first identification of ALC increase rate as a potential marker for treatment response. "It makes sense that patients showing robust immune responses are the ones having better progression free survival and better overall survival," Gandler explained.

The biomarker offers particular advantages for clinical implementation because checking a patient's ALC can be performed using existing hospital resources at relatively low cost, making it accessible across different healthcare settings.

Future Research Directions

The study forms part of a larger research initiative led by senior author Anthony Stack, DO, an Assistant Professor in the Blood Cancer and Cellular Therapy Institute at Fox Chase. Stack's broader effort aims to better understand CAR-T cell therapy, optimize its use, and evaluate its effects across different patient populations.

Researchers plan to extend their investigation to study ALC trends in other patient populations, including those receiving lisocabtagene maraleucel查看药品详情, a different type of CAR-T cell therapy. This expansion could potentially validate the biomarker's utility across multiple CAR-T platforms and patient subgroups.